The leadership void at the U.S. Food and Drug Administration (FDA) has prompted a significant groundswell of support from the…
Read More
Ginkgo Bioworks CEO Jason Kelly Discusses Autonomous Labs and the Future of Biopharma R&D
The landscape of biopharmaceutical research and development (R&D) is undergoing a seismic shift, driven by the integration of advanced robotics…
Read More
The Autonomous Revolution: How Ginkgo Bioworks is Driving a Paradigm Shift in Biopharma R&D
The biopharmaceutical industry, long reliant on the meticulous, hands-on work of human researchers, is on the cusp of a profound…
Read More
Ginkgo Bioworks CEO Jason Kelly Discusses Autonomous Labs and the Future of Biopharma R&D
The biopharmaceutical industry is on the cusp of a profound transformation, driven by the burgeoning integration of artificial intelligence (AI)…
Read More
Biogen Secures Global Rights to TJ Biopharma’s Felzartamab in Landmark $850 Million Deal, Aiming to Disrupt Multiple Myeloma Treatment Landscape
Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More
AbbVie Secures Up to $745 Million in Pain Pipeline Deal with Chinese Biopharma Haisco
AbbVie, a global biopharmaceutical giant, has finalized a significant strategic collaboration with Haisco Pharmaceutical Group, a prominent Chinese biopharmaceutical company.…
Read More
Jeito Capital’s Second Fund Closes Above Target, Bolstering European Biopharma Investment to Over €1.6 Billion
Global independent private equity fund Jeito Capital has achieved a significant milestone in European biopharma investment with the successful closure…
Read More
US Import Tariffs Fail to Deter Biopharma Giants as European Contract Manufacturing Surges for FDA-Approved Drugs
The biopharmaceutical industry is demonstrating a significant and counterintuitive trend in 2025, with companies increasingly channeling investments into European-based contract…
Read MoreYOU MAY HAVE MISSED
